While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Y-mAbs Therapeutics, Inc. (YMAB)
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Y-mAbs Therapeutics, Inc. NASDAQ:YMAB ) share price has soared 142% in the last 1 year. Most would be very happy with that, especially in just one year! But it's down 9.5% in the last week. Zooming out, the stock is actually down 55% in the last three years. Since the long term performance has been good but there's been a recent pullback of 9.5%, let's check if the fundamentals match the share price. Y-mAbs Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. Y-mAbs Therapeutics grew its revenue by 1.8% last year. That's not a very high growth rate considering it doesn't make profits. In contrast, the share price took off d
Show less
Read more
Impact Snapshot
Event Time:
YMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YMAB alerts
High impacting Y-mAbs Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
YMAB
News
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.MarketBeat
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock.MarketBeat
- Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer ResearchGlobeNewswire
- Y-mAbs to Participate in Upcoming Investor Conferences in September [Yahoo! Finance]Yahoo! Finance
- Y-mAbs to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswire
YMAB
Earnings
- 8/12/24 - Miss
YMAB
Sec Filings
- 9/20/24 - Form 8-K
- 9/20/24 - Form 4
- 9/17/24 - Form 4
- YMAB's page on the SEC website